Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer

Giandomenico Roviello, Raffaele Conca, Alberto D'Angelo, Andrea Giovanni Multari, Giovanni Paganini, Giorgio Chiriacò, Roberto Petrioli, Silvia Paola Corona, Pietro Rosellini, Michele Aieta

Research output: Contribution to journalArticle


PURPOSE: The aim of this study was to evaluate if the occurrence of neutropenia is correlated with response to ramucirumab plus paclitaxel for metastatic gastric cancer.

METHODS: This is a retrospective study of patients treated with ramucirumab plus paclitaxel.

RESULTS: Fifty-three patients were evaluated. Among these, 10 patients (26.5%) developed grade ≥3 neutropenia. Patients with grade ≥3 neutropenia reported a progression-free survival of 6.6 months (95% confidence interval 3.3-8.4) and overall survival of 11 months (95% confidence interval 5.9-13.1) vs. 4.4 months (95% confidence interval 3.9-5.2) and 8.7 months (95% confidence interval 7.8-10.1) respectively in patients' group with lower grade events.

CONCLUSION: Our analysis seems to suggest that the occurrence of neutropenia predicts response to treatment with ramucirumab and paclitaxel.

Original languageEnglish
Pages (from-to)632-636
JournalAnti-Cancer Drugs
Issue number6
Early online date31 Jan 2020
Publication statusE-pub ahead of print - 31 Jan 2020

Cite this